本文選題：二次議價 + 藥價虛高　； 參考：《衛(wèi)生經(jīng)濟研究》2016年02期

【摘要】：當前,治理藥價虛高的各項舉措——政府控制、招標采購、醫(yī)保議價,都收效甚微;"二次議價"脫穎而出,卻受到了諸多責難,一是把不屬于"二次議價"應(yīng)該承載的職能強加到"二次議價"頭上,二是把可能導致的問題斷言成必然會出現(xiàn)的問題。對此,加強對藥品"二次議價"的管理才是正確的選擇,而非"一禁了之"。
[Abstract]:At present, the various measures to deal with the false high drug prices-government control, bidding and procurement, and medical insurance bargaining-have had little effect. "second bargaining" has come to the fore, but it has been criticized by many people. One is to impose the functions which should not belong to "second bargaining" on the head of "second bargaining", the other is to assert the possible problems as inevitable problems. Therefore, it is the right choice to strengthen the management of the second negotiation of drugs, not to ban it.
【作者單位】： 安徽省農(nóng)村衛(wèi)生協(xié)會;
【分類號】：R95

【相似文獻】

相關(guān)期刊論文 前1條

1 沈洪濤;梁雪峰;李東風;;中國藥品價格治理困境與改進建議[J];中國軟科學;2012年02期

，

本文編號：2026612